Breaking News, Promotions & Moves

Aerami Therapeutics Expands Management Team

Joshua Ziel named COO and interim CEO.

Aerami Therapeutics, a clinical stage biopharmaceutical company dedicated to the treatment of serious and rare cardiopulmonary conditions, appointed Joshua Ziel, chief operating officer and CEO as the company advances AER-901 into Phase 2. In addition, the company appointed Gary Burgess, chief medical officer, and Sarah Fritchley, senior vice president, clinical development, and operations. Ziel spent the past five years focused on strategic planning for potential reverse remodeling agents...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters